Prostaglandin E 2 (PGE 2 ) is an inflammatory mediator often used to increase CCR7 expression in the dendritic cells (DC) used as cancer vaccines and to enhance their responsiveness to lymph-nodeassociated chemokines. Here, we show that high surface expression of CCR7 on PGE 2 -matured DCs is associated with their suppressed production of the endogenous CCR7-ligand, CCL19, and is reversible by exogenous CCL19. In contrast to the PGE 2 -matured DCs, DCs matured in the presence of TLR-ligands and interferons produce high levels of both CCL19 and CCR7 mRNA/protein, but show selectively-reduced expression of surface CCR7, which is compensated after DC removal from the CCL19-rich maturation environment. In accordance with these findings, PGE 2 -matured DCs show significantly-higher in vitro migratory responsiveness to lymph node-associated chemokines directly after DC generation, but not after additional short-term culture in vitro, nor in vivo in patients injected with 111 In-labelled DCs. The differences in CCL19-producing ability imprinted during DC maturation result in their different abilities to attract CCR7 + naïve T cells. Our data help to explain the impact of PGE 2 on CCR7 expression in maturing DC and demonstrate a novel mechanism of regulatory activity of PGE 2 , mediated by the inhibition of DC's ability to attract naïve T cells.
Introduction
Prostaglandin E2 (PGE 2 ) is an inflammatory mediator with suppressive activity at several levels of the immune response [1] [2] [3] . PGE 2 selectively impairs the production of IL-2 and IFNγ in T cells 4, 5 inhibits the responsiveness to T cell-activating and Th1-driving cytokines such as IL-2 and IL-12p70 6, 7 , blocks the production of DC-produced pro-inflammatory cytokines, including IL-12p70 [8] [9] [10] , and induces the production of IL-12R antagonist IL-12p40 homodimer 11, 12 . Recently, PGE 2 has been also shown to promote the ability of DCs to preferentially attract the inhibitory T(reg) subset of CD4 + T cells 13 and to directly promote the development of Tregs 14, 15 .
In apparent contrast to these suppressive functions, PGE 2 also has been reported to synergize with tumor necrosis factor-alpha (TNFα) in the induction of DC maturation 10, 16 , and in promoting CCR7 expression and the chemotactic responsiveness of DCs to CCL19 and CCL21 [17] [18] [19] , the two CCR7 ligands known to promote DC entry into lymph nodes [20] [21] [22] . These observations opened the possibility that PGE 2 may also support the induction of antigen-specific immune responses by promoting the migration of Ag-carrying DCs to the draining lymph nodes and their interaction with lymph-node-based naïve and central memory T cells. Based on these observations, PGE 2 is frequently included in the cytokine cocktails 16 used to induce mature DCs for clinical use as vaccines against cancer 23 .
Taking into account these apparently paradoxical effects of PGE 2 on DC functions, and guided by the observations from other cell systems that the surface levels of chemokine receptors can be regulated by their chemokine ligands [24] [25] [26] [27] , we tested the impact of PGE 2 on the regulation of the CCR7-CCL19/21 system in maturing DCs.
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Materials and methods

Media and reagents
Serum-free CellGro DC medium (CellGenix, Freiburg, Germany) was used for the DC cultures. The following factors were used to generate mature DC: Recombinant human (rhu) granulocyte macrophage colony-stimulating factor (GM-CSF) and IL-4 (gifts from Schering-Plough, Kenilworth, NJ); IFN-α (Intron A-IFN-α-2b, Schering-Plough); rhuTNF α, rhuIL-1β, and rhuIFN-γ (Strathmann Biotech, Hannover, Germany); rhuIL-6 (Genzyme Cambridge, MA); PGE 2 and poly-I:C (both from Sigma, St. Louis, MO). CD40L-transfected J558 cells 28 (gift from Dr. P. Lane, University of Birmingham, United Kingdom) were used as an equivalent to activated CD4 + T cells 28, 29 .
Recombinant CCL19 and CCL21 were purchased from Peprotech, Rocky Hill, NJ. FITC-labeled CCR7-specific antibody for flow cytometry (clone 150503, R&D Systems, Minneapolis, MN) and the relevant isotype control (IgG2a) used for FACS staining were obtained from R& D systems. CCR7
blocking antibody (3D12) was purchased from BD Biosciences, San Jose, CA.
DC cultures
Peripheral blood mononuclear cells (PBMCs) obtained from healthy donors were isolated with lymphocyte separation medium (CellGro Mediatech, Herndon, VA). Monocytes were isolated on density gradients, using Percoll (Sigma, St. Louis, MO) or Isolate (Irving Scientific, Santa Ana, CA)
followed by plastic adherence, as described 29, 30 . Monocytes were cultured for 6 days in 24-well plates (Falcon, Becton Dickinson Labware, Franklin Lakes, NJ) at 5 x 10 5 cells per well in rhu GM-CSF and IL-4 (both 1,000 IU/mL). On day 6, DC maturation (48 hours) was induced using the indicated combinations of the following factors: IL-1β (25 ng/mL); TNFα (50 ng/mL), IFNγ (1,000 units/mL); IL-6 (1,000 units/mL); PGE 2 (10 -6 M); Poly-I:C (20 μg/mL); IFNα (3,000 units/mL) 30 .
Isolation of naïve CD4 + T cells
Mononuclear cells from peripheral blood of healthy donors were isolated on density gradient using 
Analysis of in vitro chemotaxis
DC chemotaxis assays were performed in 96 transwell plates with 5μm pore size polycarbonate filter 
Analysis of DC migration in vivo in melanoma patients:
The clinical trial was approved by the ethics committee of the University of Heidelberg. Patients with stage IIIc-IV melanoma were eligible. DCs for clinical use were generated under cGMP conditions from autologous monocytes obtained by leukapheresis. Monocytes were selected using CD14 microbeads (CliniMACS, Miltenyi Biotech, Bergisch Gladbach, Germany) and cultured in CellGro
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From DC medium (CellGenix) supplemented with GM-CSF (800 IU/ml, Novartis, Nurnberg, Germany) and IL-4 (1000 IU/ml, CellGenix, Freiburg, Germany) for 6 days. On day 6 maturation was induced by either (for sDCs) TNF-α (5 ng/ml, Beromun, a gift from Boehringer-Ingelheim), IL-1β (2 ng/ml, CellGenix), IL-6 (5 ng/ml, CellGenix), and PGE 2 (1 µg/ml; Dinoproston, Pfizer, Berlin, Germany) or (for αDC1s) a cocktail of TNF-α (50 ng/ml), IL-1β (25 ng/ml), IFN-γ 1000 U/ml (Immukin, Boehringer-Ingelheim, Biberach, Germany) INF-α2a (1000 U/ml; Roferon A, Roche, Germany), and
Poly I:C (20 µg/ml; Sigma-Aldrich, Seelze, Germany). DCs were labeled with (1. In-labeled DC were injected intradermally on both upper thighs (αDC1s: right leg; sDCs: left leg), 10 cm distal to the inguinal lymph nodes. Migration was followed by scintigraphic imaging with a SPECT/CT camera (Hawkeye, GE Healthcare, Munich, Germany) directly after injection, and 1, 24, and 48 hours after injection. We performed whole body scans images for 20 minutes (10cm/min) and single planar scans of the pelvis for 10 minutes. Activity that accumulated in lymph nodes was quantified by region of interest analysis.
Statistical analysis:
Chemokine dose-responsiveness of DCs in vitro was analyzed by ANOVA, while the in vivo migration was analyzed by Wilcoxon's matched-pair test. In all other cases, the data were evaluated using Student's t-test (two-tailed), with p <0.05 considered as significant.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Results: PGE 2 -matured "standard" (s)DC and αDC1s show transient differences in CCR7 expression and CCR7 responsiveness in vitro, but similar lymph node-migratory function in vivo. PGE 2 -matured "standard" (s)DC and αDC1 are two types of mature DCs that can be generated in clinically-applicable serum free conditions. While the PGE 2 -based protocols of DC maturation have been shown to be associated with suppression of IL-12p70 production [10] [11] [12] 30 , the ability of PGE 2 to enhance the DC expression of CCR7 and in vitro migratory responsiveness to CCL19 and CCL21 [17] [18] [19] (CCR7 ligands guiding DCs to lymph nodes [20] [21] [22] 31 ) led to the application of PGE 2 in inducing mature "standard" DCs for clinical applications 16, 23 . In contrast to such IL-1β/TNFα/IL-6/PGE 2 -induced "standard" (s)DCs, mature type-1-polarized DCs obtained in the presence of TLR-ligands and interferons 30, [32] [33] [34] (including IL-1β/TNFα/IFNα/IFNγ/poly-I:C-induced, type-1-polarized DCs; αDC1) 30 , are capable of producing much higher levels of IL-12 and inducing tumor-specific
CTLs in vitro 30, 33, 35 , but show lower in vitro migratory responsiveness to CCR7-binding chemokines 30 .
In accordance with previous observations 30, 35 , PGE 2 -matured DCs showed statistically higher surface CCR7 expression than αDC1s ( Figure 1A, left) , and elevated ability to migrate towards CCL21, the lymph-node-associated CCR7 ligand ( Figure 1A, right) , despite significant variability of the magnitude of such differences observed in DC preparations from different donors. However, even the most profound differences in CCR7 expression on sDCs and αDC1s observed in some donors This compensation of the differences in surface CCR7 expression was reflected by the elimination of differences in migratory capacity in vitro ( Figure 1C ). In accord with the ability of the differentially-matured DCs to compensate for the maturationassociated differences in CCR7 expression and responsiveness to lymph-node-produced CCR7 ligands) also in vivo, sDCs and αDC1s showed similar ability to migrate to the draining lymph nodes, following their intradermal injection ( Figure 1D ; αDC1s: right leg; sDCs: left leg). We observed retention of the radioactivity at the injection site of 79±4% and 55±2% after 24 hours and 48 hours, respectively, with nodal accumulation starting to be detectable at 24 hours and detectable in all cases at 48 hours. Similar to earlier studies, the overall migratory effectiveness of all DCs was within the range of 0.69% to 4.6% with a single preparation migrating with 9% effectiveness (Figure 1D) . In four individuals, the migration of sDCs (range: 0.69% to 9.1%) was higher than the migration of αDC1s (range: 1.1% to 3.7%), while αDC1s were superior in two individuals of the six tested.
Selectively-enhanced surface CCR7 expression on PGE 2 -matured DCs occurs despite reduced levels of CCR7 gene expression and is abrogated by exogenous CCL19. In an attempt to address the mechanism of the transient differences in CCR7 expression between sDCs and αDC1s, we compared surface and intracellular CCR7 protein levels and the expression of CCR7 mRNA.
Unexpectedly, even in the donors showing the most pronounced differences in surface CCR7 expression (Figure 2A, left) , we could not detect such differences when analyzing the total CCR7 protein levels in permeabilized DCs (Figure 2A, Middle) . Even more strikingly, the PGE 2 -matured sDC, expressed substantially reduced, rather than enhanced, levels of CCR7 mRNA (Figure 2A, 
right).
Prompted by this dissociation between the levels of surface CCR7 protein and CCR7 mRNA expression and by previous reports showing that surface levels of chemokine receptors can be affected by ligand-induced internalization [24] [25] [26] [27] , we tested whether the differences in surface expression of CCR7 between DCs and αDC1s can be abolished by exogenous CCR7 ligands. In accordance with previous reports [24] [25] [26] [27] , we could not detect any impact of CCL21 on surface CCR7 expression Figure 1) . However, the addition of CCL19, the only DC-produced CCR7 ligand (see below) strongly reduced the surface levels of CCR7 expression of sDCs (Figure 2B, Top) . In contrast to its impact on surface expression of CCR7, CCL19 treatment did not affect the overall levels of CCR7 in sDCs (or αDC1s; Figure 2B , Bottom).
PGE 2 -matured DCs show suppressed production of CCL19: PGE 2 is a powerful inhibitor of CCL19 production by human DC
Guided by the selectively enhanced expression of surface CCR7 (but not total cell-associated CCR7 protein or CCR7 mRNA) in PGE 2 -matured DCs and by the ability of exogenous CCL19 to abrogate that advantage, we compared the ability of PGE 2 to affect the production of endogenous CCR7 ligands by human DCs. In accordance with the possibility that the differences in endogenous CCL19 production may affect the rate of internalization of CCR7, we observed high CCL19 protein secretion and high expression of CCL19 mRNA selectively in αDC1s, but not sDC ( Figure 3A 
Conditions of maturation determine the ability of mature DCs to produce CCL19 after subsequent (re)activation
In order to assess the stability of the maturation-induced differences in CCL19 production between the DCs matured in the absence and presence of PGE 2 , we analyzed the production of this factor during DC maturation (during direct exposure to interferons and TLR-Ls, or PGE 2 ) and after DC removal from these different maturation environments and upon their further culture in the absence or presence of CD40L, used as a model of interaction the differentially-matured DCs with CD40L-expressing CD4 + T cells 28, 29 .
We observed that while the difference in CCL19 production between the DCs maturing in the absence or presence of PGE 2 was reduced after removal of DCs from the maturation cultures, it was restored after subsequent DC reactivation ( Figure 3C ). The enhanced CCL19 production in αDC1s
was reduced in the DCs harvested and re-cultured for 24 hours in the absence of maturation-inducing factors, but was restored to similarly high or higher levels after DC harvesting and subsequent CD40L stimulation. In contrast to αDC1s, isolated sDCs failed to produce significant amounts of CCL19 either spontaneously or after subsequent stimulation with CD40L ( Figure 3C ), despite the absence of PGE 2 at this stage. These data indicate that the conditions of DC maturation prime DC for subsequent ability to secrete CCL19 in neutral environments and suggest that DC matured in different conditions may have different abilities to interact with CCL19-sensitive CCR7-expressing T cells (such as naïve and central memory T cells) after reaching the draining lymph nodes.
PGE 2 -matured DC show impaired ability to attract naïve T cells
In order to verify whether the CCL19 produced by αDC1 is indeed functional, we evaluated the ability of αDC1s and sDCs to attract CCR7-expressing naïve CD4 + T cells. The contribution of the CCR7 pathway was determined using CCR7 blocking antibodies. As shown in Figure 4 , while high numbers of naïve CD4 + T cells migrated towards αDC1 supernatants, sDCs were completely
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As expected, the migration of naïve T cells was completely abolished in the presence of CCR7 blocking antibody.
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Discussion:
Our data demonstrate a novel function of a chronic-inflammatory mediator, PGE 2 , as a powerful inhibitor of DC production of CCL19, the key chemokine attracting naïve and central-memory T cells. They show that PGE 2 is a dominant inhibitor of the CCL19 production induced by TNFα, interferons, or TLR-Ls (TLR3 ligand poly-I:C or TLR4 ligand, LPS; see Figure 3B ).
The stability of the maturation-induced ability to produce CCL19 indicate that the conditions of DC maturation in peripheral tissues may affect their ability to interact with naïve or central memory T cell subsets within the lymph nodes. Although the elevated CCL19 production by the DCs maturing in the presence of TNFα, interferons and TLR-Ls (rather than PGE 2 ) is rapidly terminated after DCs leave the presence of interferon-and TLR-L-dominated environment, Ag-carrying DC1 are highly likely to receive secondary chemokine-inducing signals after reaching the lymph nodes from CD40L-expressing Th cells, resulting in a second wave of CCL19 production by interferon-and TLR-Lprimed DCs (see Figure 3C ) and additional recruitment of naïve and central memory T cells.
The current data helps to understand the complex role of PGE 2 in the regulation of antigenspecific immune responses and the paradoxical effects of PGE 2 on DC functions. PGE 2 is an inflammatory mediator over-expressed in multiple inflammatory states, but prevalent at late stages of inflammatory reactions and in chronic inflammation [1] [2] [3] . PGE 2 was shown to suppress T cell proliferation and their production of key proinflammatory and antitumor cytokines in direct and indirect manner [4] [5] [6] [7] [8] [9] [10] [11] [12] , as well as to promote the interaction of DCs with Tregs 13 and to directly promote Treg development 14, 15 . Paradoxically however, the ability of PGE 2 to promote the in vitro chemotactic responsiveness of DCs to CCL19 and CCL21 [17] [18] [19] , the two CCR7 ligands directing activated DCs into lymph nodes [20] [21] [22] , suggested that PGE 2 may also support antigen-specific immune responses and led to applications of PGE 2 -based cytokine cocktails in preparation of DC-based vaccines.
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The current results help to reconcile these paradoxical observations and to explain the ability of PGE 2 to enhance the expression of CCR7 on the surface of maturing DCs. We observed that the enhanced CCR7 expression on the surface of PGE 2 -matured DCs occurs despite their reduced, rather than enhanced, expression of CCR7 mRNA and it is reversed by exogenous CCL19, the CCR7 ligand known to induce CCR7 internalization [24] [25] [26] [27] that is selectively produced by the DCs matured in the absence of PGE 2 . These data, jointly with the lack of differences at the level of total (surface plus intracellular) CCR7 protein expression, argue that the suppressed production of CCL19, preventing ligand-induced CCR7 internalization, is the key factor responsible for enhanced surface CCR7 expression in DCs maturing in the presence of PGE 2 .
Importantly, the differences in surface CCR7 expression between the DCs maturing in the absence or presence of PGE 2 are rapidly compensated following DC removal from the maturation cultures, and after the cessation of high-level production of endogenous CCL19 in DCs matured in the absence of PGE 2 . The reduced in vitro migratory function of DCs maturing in the absence of PGE 2 was clearly evident directly after DC removal from the CCL19-rich maturation cultures, but reduced or eliminated following additional culture of DCs in the absence of CCL19 (Figure 3 ). In accordance with these observations, our current in vivo data ( Figure 1D ) also did not demonstrate an advantage of PGE 2 -matured DCs in lymph-node homing. However, they do not preclude the possibility that such an advantage can be demonstrated in larger studies. In either case, our current observations suggest that any potential advantage of PGE 2 in promoting DC migration needs to be balanced against its negative impact on the CCL19 production by DCs.
The ability of PGE 2 , the predominant inflammatory mediator during late stages of inflammation, to program local DCs for preferential interaction with T regs with the concomitant inhibition of their ability to attract type-1 immune effector cells 13 , and naïve and central memory T cells (the current data) helps to explain the dominance of the suppressive effects at later stage of 
